Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The anti-CD274 F(ab) fragment is a monovalent antibody fragment derived from the papain digestion of the rat-anti-mouse CD274 (PD-L1) monoclonal antibody, specifically clone MIH6. As a checkpoint inhibitor, it targets Programmed cell death 1 ligand 1 (CD274/PD-L1) on the surface of tumor cells. By binding to CD274, the fragment competitively inhibits its interaction with the PD-1 receptor on T cells, thereby preventing the dephosphorylation of downstream signaling molecules like ZAP70 and PI3K. This blockade reverses the state of T-cell exhaustion—characterized by high expression of PD-1 and LAG3—and restores the proliferative and cytotoxic capacity of tumor-specific T cells. Preclinical studies in the TCL1 transgenic mouse model demonstrate that treatment with this fragment enhances the clearance of malignant B cells in vivo, suggesting its potential as a therapeutic strategy for chronic lymphocytic leukemia (CLL).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-CD274 F(ab) fragment.